Tempus AI to Present Six Abstracts on Precision Oncology Research at CTOS 2026 Annual Meeting
Tempus AI, a company specializing in molecular profiling, artificial intelligence, and clinical data analysis, is scheduled to present six abstracts at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting in Seoul, South Korea, from November 18–21. These presentations will include three oral presentations. The research focuses on various aspects of precision oncology, particularly in rare cancers like sarcomas and gastrointestinal stromal tumors (GIST). Studies will examine molecular biomarkers, tumor classification, treatment response, and genetic alterations. One study will investigate melanoma-associated antigen A4 (MAGE-A4) messenger RNA (mRNA) expression and the tumor immune microenvironment as potential biomarkers in sarcoma. Two other studies will focus on GIST, identifying a DNA damage response (DDR) transcriptional signature and classifying GIST into prognostic risk groups using transcriptomic profiling. Additional research will cover transcriptional programs associated with pazopanib...